CDP7851/AMG 785 (UCB/Amgen) enters Phase III for Osteoporosis

UCB and Amgen have announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase III clinical trial program for the treatment of Post Menopausal Osteoporosis. The Phase III program includes a multicenter, international, randomized, double-blind, placebo-controlled, parallel-group, two-year study in more than 5,000 postmenopausal women with osteoporosis. The primary endpoint will evaluate the incidence of new vertebral fractures at 12 months. Initial results from the Phase III program are expected by the end of 2015.CDP7851/AMG 785 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, CDP7851/AMG 785 is designed to increase the amount of bone in the skeleton.